A Treatment Study for Premenstrual Syndrome (PMS)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00001259 |
|
Recruitment Status :
Completed
First Posted : November 4, 1999
Results First Posted : March 2, 2023
Last Update Posted : March 2, 2023
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
This study examines the effects of estrogen and progesterone on mood, the stress response, and brain function and behavior in women with premenstrual syndrome.
Previously this study has demonstrated leuprolide acetate (Lupron (Registered Trademark)) to be an effective treatment for PMS. The current purpose of this study is to evaluate how low levels of estrogen and progesterone (that occur during treatment with leuprolide acetate) compare to menstrual cycle levels of estrogen and progesterone (given during individual months of hormone add-back) on a variety of physiologic measures (brain imaging, stress testing, etc.) in women with PMS.
PMS is a condition characterized by changes in mood and behavior that occur during the second phase of the normal menstrual cycle (luteal phase). This study will investigate possible hormonal causes of PMS by temporarily stopping the menstrual cycle with leuprolide acetate and then giving, in sequence, the menstrual cycle hormones progesterone and estrogen. The results of these hormonal studies will be compared between women with PMS and healthy volunteers without PMS (see also protocol 92-M-0174).
At study entry, participants will undergo a physical examination. Blood, urine, and pregnancy tests will be performed. Cognitive functioning and stress response will be evaluated during the study along with brain imaging and genetic studies.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Premenstrual Syndrome Menstruation Disturbances | Drug: Leuprolide Drug: Estradiol Patches Drug: Progesterone Drug: Placebo patch Drug: Placebo injection Drug: Placebo suppository | Phase 1 |
This protocol is designed to accompany Clinical Protocol # 81-M-0126, The Phenomenology and Biophysiology of Menstrually-Related Mood and Behavioral Disorders. Its original purposes were as follows: 1) to evaluate the efficacy of the gonadotropin releasing hormone (GnRH) agonist depot leuprolide acetate (Lupron) in the treatment of menstrually-related mood disorders (MRMD) by determining whether mood and behavioral symptoms are eliminated when the cyclic secretion of both gonadotropic hormones and gonadal steroids is suppressed, and 2) to determine the possible relevance of gonadal steroids to affective state by sequentially replacing estradiol and progesterone during continued GnRH suppression in those patients whose premenstrual symptoms remit following administration of the GnRH agonist. We observed that GnRH agonist induced ovarian suppression was an effective treatment compared to placebo in women with MRMD. Additionally, women with MRMD but not asymptomatic controls (participating in companion protocol 92-M-0174) experienced a recurrence of mood and behavioral symptoms when either estradiol or progesterone (but not placebo) was added back. These data suggest that women with MRMD have a differential sensitivity to the mood destabilizing effects of gonadal steroids.
Having established that women with MRMD show a differential behavioral response to estrogen and progesterone, we now hope to identify the underlying mechanisms and physiologic concomitants of the differential behavioral sensitivity by performing studies (described in companion protocols) under the three hormonal conditions created by this protocol, and comparing results obtained with those seen in normal controls (Protocol #92-M-0174). Planned studies include the following: cognitive testing, brain imaging [(3D-positron emission tomography (PET), functional magnetic resonance imaging (FMRI), magnetic resonance spectroscopy (MRS)] and genetic studies including induced pluripotent cells.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 60 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Crossover Assignment |
| Masking: | Triple (Participant, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | The Treatment of Menstrually-Related Mood Disorders With the Gonadotropin Releasing Hormone (GnRH) Agonist, Depot Leuprolide Acetate (Lupron) |
| Actual Study Start Date : | August 11, 1992 |
| Actual Primary Completion Date : | February 6, 2020 |
| Actual Study Completion Date : | February 6, 2020 |
| Arm | Intervention/treatment |
|---|---|
|
Placebo Comparator: Study 1, Phase 1, Assignment 1 - Placebo
As part of double Blind randomized trial, participants in Assignment 1 were randomized to 8 weeks of placebo (P) injections (1 injection per month). These participants then continued on to Study 2 after completion of 8 weeks of placebo injections.
|
Drug: Placebo injection
Placebo given intramuscularly monthly |
|
Experimental: Study 1, Phase 1, Assignment 2 - GnRH agonist injections (Lupron-L only)
As part of double Blind randomized trial, participants in Assignment 2 were randomized to 8 weeks of GnRH agonist treatment 3.75 mg given intramuscularly monthly. Those who exhibited a remission of symptoms after 8 weeks continued on to receive one more month of GnRH agonist treatment (12 weeks total) and then entered Study 1, Phase 2.
|
Drug: Leuprolide
Eight to 12 weeks of GnRH agonist, Leuprolide Acetate 3.75 mg given intramuscularly monthly |
|
Experimental: Study 1, Phase 2, Arm 1 - Estradiol, then progesterone
12 weeks of GnRH agonist treatment 3.75 mg given intramuscularly monthly. Additionally, 4 weeks of transdermal Estradiol (100mcg/day by skin patch) and placebo suppositories. Week 5 involves 100mcg/day transdermal Estradiol and active Progesterone suppositories (200mg vaginally twice/day). Followed by 1-2 weeks (weeks 6-7) washout period. Then crossover to 5 weeks (week 8-12) of Progesterone suppositories (200mg vaginally twice/day) and placebo patches.
|
Drug: Leuprolide
Eight to 12 weeks of GnRH agonist, Leuprolide Acetate 3.75 mg given intramuscularly monthly Drug: Estradiol Patches Transdermal Estradiol, 100mcg/day by skin patch Drug: Progesterone Progesterone suppository, 200mg vaginally twice/day Drug: Placebo patch Placebo by skin patch Drug: Placebo suppository Placebo vaginal suppository |
|
Experimental: Study 1, Phase 2, Arm 2 - Progesterone, then estradiol
12 weeks of GnRH agonist treatment 3.75 mg given intramuscularly monthly. Additionally, 5 weeks of Progesterone suppositories (200mg vaginally twice/day) and placebo patches. Followed by 1-2 weeks (weeks 6-7) washout period. Then crossover to 4 weeks (weeks 8-11) of transdermal Estradiol (100mcg/day by skin patch) and placebo suppositories. Week 12 involves 100mcg/day transdermal Estradiol and active Progesterone suppositories (200mg vaginally twice/day).
|
Drug: Leuprolide
Eight to 12 weeks of GnRH agonist, Leuprolide Acetate 3.75 mg given intramuscularly monthly Drug: Estradiol Patches Transdermal Estradiol, 100mcg/day by skin patch Drug: Progesterone Progesterone suppository, 200mg vaginally twice/day Drug: Placebo patch Placebo by skin patch Drug: Placebo suppository Placebo vaginal suppository |
|
Experimental: Study 2, Phase 1 - GnRH agonist injections (Lupron-L only)
Eight to 12 weeks of GnRH agonist treatment 3.75 mg given intramuscularly monthly.
|
Drug: Leuprolide
Eight to 12 weeks of GnRH agonist, Leuprolide Acetate 3.75 mg given intramuscularly monthly |
|
Experimental: Study 2, Phase 2, Arm 1 - Estradiol, then progesterone
12 weeks of GnRH agonist treatment 3.75 mg given intramuscularly monthly. Additionally, 4 weeks of transdermal Estradiol (100mcg/day by skin patch) and placebo suppositories. Week 5 involves 100mcg/day transdermal Estradiol and active Progesterone suppositories (200mg vaginally twice/day). Followed by 1-2 weeks (weeks 6-7) washout period. Then crossover to 5 weeks (week 8-12) of Progesterone suppositories (200mg vaginally twice/day) and placebo patches.
|
Drug: Leuprolide
Eight to 12 weeks of GnRH agonist, Leuprolide Acetate 3.75 mg given intramuscularly monthly Drug: Estradiol Patches Transdermal Estradiol, 100mcg/day by skin patch Drug: Progesterone Progesterone suppository, 200mg vaginally twice/day Drug: Placebo patch Placebo by skin patch Drug: Placebo suppository Placebo vaginal suppository |
|
Experimental: Study 2, Phase 2, Arm 2 - Progesterone, then estradiol
12 weeks of GnRH agonist treatment 3.75 mg given intramuscularly monthly. Additionally, 5 weeks of Progesterone suppositories (200mg vaginally twice/day) and placebo patches. Followed by 1-2 weeks (weeks 6-7) washout period. Then crossover to 4 weeks (weeks 8-11) of transdermal Estradiol (100mcg/day by skin patch) and placebo suppositories. Week 12 involves 100mcg/day transdermal Estradiol and active Progesterone suppositories (200mg vaginally twice/day).
|
Drug: Leuprolide
Eight to 12 weeks of GnRH agonist, Leuprolide Acetate 3.75 mg given intramuscularly monthly Drug: Estradiol Patches Transdermal Estradiol, 100mcg/day by skin patch Drug: Progesterone Progesterone suppository, 200mg vaginally twice/day Drug: Placebo patch Placebo by skin patch Drug: Placebo suppository Placebo vaginal suppository |
- Mean Beck Depression Inventory Score [ Time Frame: Placebo: Weeks 6 and 8 of Placebo; Lupron only: Weeks 6 and 8 or 10 and 12; Estradiol or progesterone: Weeks 2 and 4 ]
The Beck Depression Inventory (BDI) is a 21-item, self-report rating inventory that measures the severity of symptoms accompanying depression. Each item has a minimum score of 0 and a maximum score of 3, with higher numbers consistent with more severe symptoms. The score of each item is summed to amount the overall BDI score, with a minimum score of 0 and a maximum score of 63. Higher BDI scores are consistent with more severe depression. Score of 16 or greater is consistent with clinical depression.
Each participant completed the BDI every 2 weeks during each of the study phases throughout the 6-month study. Outcome measures reported consist of the average of two BDI scores from each phase of the study: the last 4 weeks of the GnRH agonist alone; weeks 6 and 8 of placebo alone; during the 4-week long estradiol phase (weeks 2 and 4 of estradiol) and the 4-week long progesterone phase (weeks 2 and 4 of progesterone).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 45 Years (Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
- INCLUSION CRITERIA:
The subjects of this study will be women who meet the criteria for MRMD as described in Protocol No. 81-M-0126, 'The Phenomenology and Biophysiology of Menstrually-related Mood and Behavioral Disorders.' In brief, these criteria include:
- history within the last two years of at least six months with menstrually-related mood or behavioral disturbances of at least moderate severity--i.e., disturbances that are distinct in appearance and associated with a notable degree of subjective distress;
- symptoms should have a sudden onset and offset;
- age 18-50;
- not pregnant and in good medical health;
-
medication free.
All patients participating in this protocol will have already participated in Protocol No. 81-M-0126 and will have a prospectively confirmed and predictable relationship between their mood disorder and the premenstrual phase of the menstrual cycle, i.e., a 30% change in severity of symptom self rating scales, relative to the range of the scale employed, during the seven days premenstrually compared with the seven days post-menstrually in two out of three months of study.
The Schedule for Affective Disorders and Schizophrenia will be administered to all patients prior to study entry. Any patient with a current axis I psychiatric diagnosis will be excluded from participating in this protocol.
Prior to treatment, a complete physical and neurological examination will have been performed and the following routine laboratory data obtained:
A. Blood
Complete blood count; thyroid function tests; cortisol; renal function tests, such as blood urea nitrogen (BUN) and creatinine; electrolytes; glucose; liver function tests.
B. Urine
Routine urinalysis; urine pregnancy test.
GnRH agonist will not be administered to any subject with significant clinical or laboratory abnormalities. The blood tests and urinalysis will be repeated 2 weeks after GnRH agonist administration to rule out any evidence of acute renal, hepatic or hematologic toxicity.
Results of Pap smear performed within one year of the onset of treatment will be obtained.
EXCLUSION CRITERIA:
The following conditions will constitute contraindications to treatment with hormonal therapy and will preclude a subject's participation in this protocol:
- current Axis I psychiatric diagnosis
- history consistent with endometriosis,
- diagnosis of ill-defined, obscure pelvic lesions, particularly, undiagnosed ovarian enlargement,
- hepatic disease as manifested by abnormal liver function tests,
- history of mammary carcinoma,
- history of pulmonary embolism or phlebothrombosis
- undiagnosed vaginal bleeding
- porphyria
- diabetes mellitus
- history of malignant melanoma
- cholecystitis or pancreatitis,
- cardiovascular or renal disease
- pregnancy
- Any woman meeting the Stages of Reproductive Aging Workshop Criteria (STRAW) for the perimenopause. Specifically, we will exclude any woman with an elevated plasma follicle stimulating hormone (FSH) level (>= 14 IU/L) and with menstrual cycle variability of > 7 days different from their normal cycle length.
- Subjects taking birth control pills will be excluded from the study.
- Subjects taking diuretics, prostaglandin inhibitors, or pyridoxine (putative treatments for MRMD) will similarly be excluded from the study
- Patients taking psychotropic agents (e.g., lithium carbonate, tricyclic antidepressants).
- All subjects will be required to use non-hormonal forms of birth control (e.g., barrier methods) to avoid pregnancy during this study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00001259
| United States, Maryland | |
| National Institutes of Health Clinical Center, 9000 Rockville Pike | |
| Bethesda, Maryland, United States, 20892 | |
| Principal Investigator: | Peter J Schmidt, M.D. | National Institute of Mental Health (NIMH) |
Documents provided by National Institutes of Health Clinical Center (CC) ( National Institute of Mental Health (NIMH) ):
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | National Institute of Mental Health (NIMH) |
| ClinicalTrials.gov Identifier: | NCT00001259 |
| Other Study ID Numbers: |
900088 90-M-0088 |
| First Posted: | November 4, 1999 Key Record Dates |
| Results First Posted: | March 2, 2023 |
| Last Update Posted: | March 2, 2023 |
| Last Verified: | January 4, 2021 |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Depression Menstrual Cycle Gonadal Steroids |
Estradiol Progesterone Mood Disorders |
|
Syndrome Premenstrual Syndrome Menstruation Disturbances Disease Pathologic Processes Leuprolide Estradiol Progesterone Estrogens |
Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Reproductive Control Agents Progestins Fertility Agents, Female Fertility Agents Antineoplastic Agents, Hormonal Antineoplastic Agents |